IP Group has participated in a $92m series C round for Pulmocide, a developer of treatments for respiratory diseases that was spun out of Imperial College London.

Pulmocide, a UK-based developer of therapies for serious acute and chronic respiratory diseases based on research at Imperial College London, secured $92m in series C commitments today from backers including commercialisation firm IP Group.
Investment company Jeito Capital led the oversubscribed round, which also attracted pharmaceutical firms Asahi Kasei Pharma, GlaxoSmithKline and Johnson & Johnson, the latter two through SR One and Johnson & Johnson Innovation – JJDC, respectively.
F-Prime Capital, an investment arm of financial services group…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in